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Abstract
Background:  PLS is a rare autosomal recessive disorder characterized by early onset
periodontopathia and palmar plantar keratosis. PLS is caused by mutations in the cathepsin C
(CTSC) gene. Dipeptidyl-peptidase I encoded by the CTSC gene removes dipeptides from the amino-
terminus of protein substrates and mainly plays an immune and inflammatory role. Several
mutations have been reported in this gene in patients from several ethnic groups. We report here
mutation analysis of the CTSC gene in three Indian families with PLS.
Methods: Peripheral blood samples were obtained from individuals belonging to three Indian
families with PLS for genomic DNA isolation. Exon-specific intronic primers were used to amplify
DNA samples from individuals. PCR products were subsequently sequenced to detect mutations.
PCR-SCCP and ASOH analyses were used to determine if mutations were present in normal
control individuals.
Results: All patients from three families had a classic PLS phenotype, which included palmoplantar
keratosis and early-onset severe periodontitis. Sequence analysis of the CTSC gene showed three
novel nonsense mutations (viz., p.Q49X, p.Q69X and p.Y304X) in homozygous state in affected
individuals from these Indian families.
Conclusions: This study reported three novel nonsense mutations in three Indian families. These
novel nonsense mutations are predicted to produce truncated dipeptidyl-peptidase I causing PLS
phenotype in these families. A review of the literature along with three novel mutations reported
here showed that the total number of mutations in the CTSC gene described to date is 41 with 17
mutations being located in exon 7.
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Background
With an incidence of 1 to 4/million, Papillon-Lefèvre Syn-
drome (PLS, MIM 245000) is a rare autosomal recessive
disorder with an onset usually by two to three years of age
[1,2]. The disease is mainly characterized by severe early
onset periodontitis, leading to premature tooth shedding
of both the deciduous and permanent teeth, alveolar bone
destruction (such that by 15 years of age the patients are
usually edentulous), and hyperkeratosis characteristically
involving the palms and soles and sometimes the knees,
elbows, knuckles, and back [1]. PLS can manifest itself as
early as 2 months of age with the appearance of hyperk-
eratotic lesions of the hands and feet [3]. Other clinical
features not often reported are an increased susceptibility
to infections (especially furunculosis and pyoderma, pyo-
genic liver abscess etc.,) with recurrent fevers in childhood
and calcification of the dura. Males and females are
equally affected with no racial predominance [3]. Approx-
imately one-third of the families show consanguinity [2].
PLS is a genetically homogeneous disorder with a locus
mapped on chromosome 11q14-q21 [4–6]. Toomes et al.
[7] have subsequently reported that loss-of-function
mutations in the cathepsin C gene result in the PLS phe-
notype. The cathepsin C gene encodes a cysteine lyso-
somal protease also known as dipeptidyl-peptidase I
which functions by removing dipeptides from the amino
terminus of the protein substrate. It also has endopepti-
dase activity. It is highly expressed in various tissues such
as the cells of the immune system (polymorphic nuclear
leukocytes, alveolar macrophages and their precursors),
and in the lungs, kidneys and other epithelial tissues [8].
Its main functions are thought to be protein degradation
and pro-enzyme activation in addition to its immunolog-
ical role [8]. The CTSC gene is over 46 kb long and con-
sists of seven exons and six introns [7]. Several mutations
have been reported in the CTSC gene in individuals from
diverse ethnic groups. In addition, mutation in this gene
was also detected in a Jewish-Hindu family with Haim-
Munk syndrome [9] and prepubertal periodontitis [10].
We report here mutation analysis of the CTSC gene in
three Indian families with members suffering from PLS.
We also present a summary of cathepsin C mutations
reported to date in PLS patients.
Methods
Patients
We have ascertained three families from the southern part
of India, IISC-PLS1, IISC-PLS2 and IISC-PLS3 with PLS
phenotype. Families IISC-PLS1 and IISC-PLS3 are non-
consanguineous, whereas family IISC-PLS2 shows con-
sanguinity. A total of 11 individuals including five
patients were recruited for the study from these three fam-
ilies. All family members were examined in detail by clini-
cians and the patients with PLS were diagnosed according
to previously established criteria [1,2,11]. This research
followed the tenets of the Declaration of Helsinki.
Informed consent was obtained from the individuals
included in this study.
PCR amplification and mutation analysis
Genomic DNA samples were isolated from peripheral
blood samples of all available members of three families
using a Wizard® Genomic DNA Extraction kit (Promega
Inc., USA). Genomic DNA from one affected member
from each family was initially PCR amplified for all seven
exons spanning the CTSC gene using pairs of exon-specific
intronic primers. The primer sequences are described in
Toomes et al. [7]. PCR amplification was carried out in a
25 µl reaction volume containing ~100 ng genomic DNA,
60 ng of each primer, 200 µmol of each dNTP, 1 unit Taq
DNA polymerase (Bangalore Genei®, India) in a standard
PCR buffer supplied by the manufacturer. Amplification
was performed in a Minicycler™ (MJ Research® Inc., USA)
under the following conditions: an initial denaturation at
95°C for 2 min was followed by 35 cycles at 94°C for 30
s, 62°C for 30 s, 72°C for 1 min and a final extension of
5 min at 72°C. PCR amplified products were purified
using a Wizard®  PCR Preps DNA Purification System
(Promega Inc., USA) and subjected to direct sequencing
using an fmol®  DNA Cycle Sequencing System kit
(Promega Inc., USA) according to the manufacturer's
instruction. Once a nucleotide change was detected in a
patient, other available members from the family were
also sequenced to determine if the change was also
present in them. PCR-SSCP and allele-specific oligonucle-
otide hybridization (ASOH) analyses were used to deter-
mine if a nucleotide change was present in ethnically
matched normal controls as described in Kumar et al. [12]
and Cormand et al. [13] respectively.
Results
All patients had a history of the onset of the disorder by
the age of 2 to 3 years. Examination of these patients
revealed that they all had severe palmar plantar kerato-
derma, and severe periodontitis (except individual II-2
from family IISC-PLS3) leading to shedding of most of
their teeth. Patient II-2 from family IISC-PLS3 had a sub-
sidence of periodontitis, as he was edentulous, having lost
all his teeth by the age of 12 years. Patients IV-3 and IV-4
from family IISC-PLS2 also had hyperkeratosis of the
knuckles, knees and elbows in addition to palmar plantar
keratoderma and severe periodontitis. Fig. 1 illustrates
clinical manifestations of PLS. Individual II-2 from family
IISC-PLS3 was known to have frequent episodes of infec-
tions especially of the skin and recurrent fevers in child-
hood, suggesting an increased susceptibility to microbial
infections. Heterozygous parents from families IISC-PLS1
and IISC-PLS2 and heterozygous siblings (IV-1 and IV-5)
from family IISC-PLS2 were unaffected.BMC Medical Genetics 2003, 4 http://www.biomedcentral.com/1471-2350/4/5
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Clinical features of PLS Figure 1
Clinical features of PLS. (A) Periodontitis affecting secondary dentition in the patient IV-3 at 16 yrs of age from the family IISC-
PLS2. (B) Orthopantomogram of oral cavity of patient IV-3 at 11 years of age from the family IISC-PLS2 with severe periodon-
titis. All teeth in this patient are permanent and there is an extensive loss of alveolar bone both in maxillary and mandibular 
arches. (C) Periodontitis in the patient IV-4 at 12 years of age from the family IISC-PLS2. (D) Orthopantomogram of oral cavity 
of patient IV-4 at 12 years of age from the family IISC-PLS2 with severe periodontitis. All teeth in this patient are permanent 
and there is an extensive loss of alveolar bone both in maxillary and mandibular arch. (E) Knuckle hyperkeratosis in the patient 
IV-4 of the family IISC-PLS2. (F) Plantar hyperkeratosis in the patient IV-3 of the family IISC-PLS2. (G) Palmar hyperkeratosis 
(punctate type) in the patient II-2 of the family IISC-PLS3.BMC Medical Genetics 2003, 4 http://www.biomedcentral.com/1471-2350/4/5
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We initially screened PCR products of all seven exons of
the CTSC gene for mutation(s) in one patient from each
family using DNA sequencing technique (Fig. 2). Once
the mutation was detected, it was confirmed in other
members of the family. Sequence analysis of the exon 1
PCR product from the patient III-1 of the family IISC-PLS1
showed a nucleotide change in a homozygous state at
position 145 from C>T (c.145C>T) which introduced a
premature stop codon in the exon 1 (p.Q49X) (Fig. 2A).
This change was also present in affected sibling III-2 in a
homozygous state, whereas both parents were hetero-
zygous for this change (Fig. 2A). PCR-SSCP analysis
showed that this change was not present in 60 normal
chromosomes (data not shown).
Three novel nonsense mutations in the CTSC gene Figure 2
Three novel nonsense mutations in the CTSC gene. The numbering of the wild type sequence is based upon the cDNA 
sequence of the CTSC gene (GenBank accession # NM-001814). (A) Pedigree diagram of the family IISC-PLS1. DNA samples 
from individuals II-4, II-5, III-1 and III-2 were analysed from this family. Direct sequencing of the PCR products from both het-
erozygous parents II-4 and II-5 and homozygous patients III-1 and III-2 are shown on the right. Arrows indicate the145C>T 
nucleotide change. (B) Pedigree diagram of the family IISC-PLS2. DNA samples from individuals III-3, III-4, IV-1, IV-3, IV-4 and 
IV-5 were analysed from this family. Direct sequencing of the PCR products from both heterozygous parents III-3 and III-4, and 
homozygous patients IV-3 and IV-4 are shown on the right. Arrows indicate the 205C>T nucleotide change. (C) Pedigree dia-
gram of the family IISC-PLS3. DNA sample from only individual II-2 was analysed from this family. Direct sequencing of the PCR 
product from the patient II-2 is shown on the right. Arrow indicates the 912 C>A change.BMC Medical Genetics 2003, 4 http://www.biomedcentral.com/1471-2350/4/5
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Sequence analysis of the exon 2 PCR-product from the
patient IV-3 of the family IISC-PLS2 showed a nucleotide
change in a homozygous state at position 205 from C>T
(c.205C>T) which introduced a premature stop codon in
the exon 2 (p.Q69X) (Fig. 2B). As expected, affected sib-
ling IV-4 from this family was also homozygous for this
change, whereas both parents (Fig. 2B) and both unaf-
fected siblings (IV-1 and IV-5) were heterozygous for this
change (data not shown). Since PCR-SSCP analysis failed
to demonstrate this change, we used ASOH analysis to
determine if this change was present in normal controls.
ASOH analysis showed that this change was not present in
60 normal chromosomes (data not shown).
Sequence analysis of the exon 7 PCR product from the
patient II-2 of the family IISC-PLS3 (Fig. 2C) showed a
nucleotide change in a homozygous state at position 912
from C>A (c.912C>A) which introduced a premature stop
codon in the exon 7 (p.Y304X). PCR-SSCP analysis
showed that this change was not present in 60 normal
chromosomes (data not shown).
Discussion
All three nucleotide changes reported here fulfilled the cri-
teria of a mutation [12] as these changes were not present
in the controls and result in the truncation of the CTSC
encoded enzyme dipeptidyl-peptidase I with the introduc-
tion of premature stop codons. The c.145C>T mutation in
the family IISC-PLS1 would be expected to produce an
abnormally short enzyme dipeptidyl-peptidase I of 49
amino acid length in contrast to a normal enzyme of 463
amino acids [8]. Similarly, the c.205C>T change in the
family IISC-PLS2 would be expected to produce a trun-
cated enzyme with 69 amino acids and the c.912C>A
mutation in the family IISC-PLS3 would be expected to
produce a truncated enzyme with 304 amino acids [8].
These nonsense mutations would reduce any residual
dipeptidyl peptidase I activity through nonsense muta-
tion-mediated decay of the transcript, which might result
in very low steady-state levels of CTSC messages leading to
the disease phenotype in patients reported in the present
study. In addition, this protein is lysosomal and may not
be transported to the organelle if truncated, leading to the
disease phenotype. It has been suggested that dipeptidyl
peptidase I is involved in a wide variety of immune and
inflammatory responses that include the activation of
phagocytic cells and T-lymphocytes, leading to the final
elimination of pathogens [7]. Therefore, inactivation of
the dipeptidyl-peptidase I due to mutations would result
in the blocking of these responses leading to infection of
the gums and surrounding tissues by pathogens, ulti-
mately leading to tooth loss. Alternatively, dipeptidyl-
peptidase I might influence periodontal disease progres-
sion through its role in epithelial differentiation or desq-
uamation. Since the sulcular and junctional epithelium
represent the first line of defense against pathogens, their
aberrant differentiation due to mutant CTSC gene may
alter the mechanical barrier to periodontal pathogens [7].
A review of the literature on the number of total muta-
tions reported in the CTSC gene shows a total of 38 muta-
tions [[3,7,14–22], http://www.genetics.pitt.edu/CTSC/]
with 27 being novel and 11 recurrent (Table 1). The total
number of known mutations in the CTSC gene is now 41.
Of these, 11 mutations are recurrent (Table 1). A majority
of mutations (a total of 17 mutations) are located in exon
7 (Table 1). Of the known mutations, 11 are nonsense, 20
are missense, 2 are insertions, 7 are deletions and 1 is a
splice site mutation (Table 1). This suggests that although
most of the mutations (a total of 17) are located in exon
7, mutations are scattered across the coding region of the
CTSC gene, suggesting that mutation analysis of the cathe-
psin C gene will require evaluation of the complete gene.
Missense mutation c.815G>C (p.R272P) has been found
in nine families including four families from Saudi Ara-
bia. The haplotype analysis has shown that these four
Saudi Arabian families have inherited this mutation from
a common ancestor [17]. Similarly, Zhang et al. [17] have
demonstrated that a recurrent nonsense mutation
c.856C>T (p.Q286X) found in three families from Turkey
has a common ancestral origin. A nonsense mutation
c.1286G>A (p.W429X) found in four families from Tur-
key has also been found to have a common ancestral ori-
gin by haplotype analysis [17]. On the other hand, it is not
clear if five recurrent mutations- c.96T>G (p.Y32X) found
in three families, splice site mutation IVS3_1G>A found
in two families, c.901G>A (p.G301S) found in three fam-
ilies, c.1015C>T (p.R339C) found in four families and
c.1040A>G (p.Y347C) found in two families- have origi-
nated from common ancestors or these mutation sites
represent mutation hotspots.
An interesting feature of the cathepsin C gene is that muta-
tions in this gene also result in two other closely related
conditions: the Haim-Munk Syndrome [9], and
prepubertal periodontitis [10]. A common clinical mani-
festation in all three syndromes is severe early-onset peri-
odontitis. Haim-Munk syndrome (HMS) is an ethnically
specific disorder described only in Jews of South Indian
origin (the so called "Cochin Jews"). The clinical pheno-
types of HMS overlap with PLS and prepubertal periodon-
titis (PPP) and include congenital keratosis
palmoplantaris, onychogryposis, periodontitis, pes pla-
nus, arachnodactyly, and acroosteolysis. Thus HMS, PPP
and PLS seem to be allelic variants. A common mutation
c.1040A>G has been shown to cause two distinct pheno-
types, PLS and PPP, suggesting that other factors such as
genetic or environmental, play a role in the ultimate phe-
notype [15]. A missense mutation c.857A>G (p.Q286R)
in the CTSC gene has been found to cause HMS [9]. ThisBMC Medical Genetics 2003, 4 http://www.biomedcentral.com/1471-2350/4/5
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Table 1: Disease-causing mutations in the cathepsin C gene detected so far.
Sl# Exon Type Mutation Effect Origin / Disease No. of 
families
1 1 Nonsense c.72C>A (p.C24X) Premature stop Moroccan 19 / PLS 1
2 1 Nonsense c.96T>G (p.Y32X) Premature stop Mexican 20, §Caucasian 20, French 19 / PLS 3
3 1 Nonsense c.145C>T (p.Q49X) Premature stop Indian A / PLS 1
4 1 Missense c.116G>C (p.W39S) AHCR** Puerto Rican 16 / PLS 1
5 2 Nonsense c.205C>T (p.Q69X) Premature stop Indian A / PLS 1
6 2 Deletion c.199_222del (p. 67_74) Frameshift * Chinese 15 / PLS 1
7 3 Missense c.380A>C (p. H127P) AHCR** French 19 / PLS 1
8 3 Missense c.415G>A (p.G139R) AHCR** §S Caucasian 20 / PLS 1
9 3 Insertion c.445_446insATGT 
(p.V149fsX157)
Frameshift & premature 
stop
Indian 15 / PLS 1
10 Splice site 
(Intron 3)
IVS3_1G>A Altered splicing Egyptian 7, Jordanian 22 / PLS 2
11 4 Nonsense c.545G>A (p.W185X) Premature stop Brazilian 21 / PLS 1
12 4 Missense c.587T>C (p.L196P) AHCR** Brazilian 3 / PLS 1
13 4 Insertion 622_623insC 
(p.H208fsX223)
Frameshift & Premature 
stop
Turkish 15 / PLS 1
14 4 Nonsense c.628C>T (p.R210X) Premature stop Lebanese7, Algerian 19 / PLS 2
15 5 Nonsense c.704G>A (p.W235X) Premature stop Iranian 15 / PLS 1
16 5 Missense c.706G>T (p.D236Y) AHCR** φ Spanish 18 / PLS 1
17 5 Deletion c.711del14 Frameshift & Premature 
stop
Algerian 19 / PLS 1
18 5 Missense c.745G>T (p.V249F) AHCR** Indian-Pakistani 7 / PLS 1
19 5 Nonsense c.748C>T (p.R250X) Premature stop Turkish 15 / PLS 1
20 5 Missense c.755A>T (p.Q252L) AHCR** Egyptian 7 / PLS 1
21 6 Missense c.815G>C (p.R272P) AHCR** Lebanese7, Turkish 15, §Caucasian20, (4) Saudi 
17, Holland19, French 19 / PLS
9
22 6 Nonsense c.856C>T (p.Q286X) Premature stop Turkish 9,14,17 / PLS 3
23 6 Missense c.857A>G (p.Q286R) AHCR** Indian 9, Spanish18 / HMS, PLS 2
24 6 Missense c.872G>A (p.C291Y) AHCR** φ Spanish 18 /PLS 1
25 7 Missense c.898G>A (p.G300S) AHCR** Φ Vietnamese 15 / PLS 1
26 7 Missense c.899G>A (p.G300D) AHCR** Saudi 17 / PLS 1
27 7 Missense c.901G>A (p.G301S) AHCR** Indian-Pakistani 7, Iranian 15, Japanese 16 / PLS 3
28 7 Missense c.902G>T (p.G301V) AHCR** Iranian 15 / PLS 1
29 7 Missense c.910T>A (p.Y304N) AHCR** Panamanian 15 / PLS 1
30 7 Nonsense c.912C>A (p.Y304X) Premature stop Indian A / PLS 1
31 7 Missense c.956A>G (p.E319G) AHCR** Iranian 15 / PLS 1
32 7 Deletion c.984del7 Frameshift & Premature 
stop
French 19 / PLS 1
33 7 Missense c.1015C>T (p.R339C) AHCR** Egyptian 7,15, Turkish10, Martinique 19 / PLS 4
34 7 Deletion c.1028_1029delCT 
(p.S343X)
Frameshift & Premature 
stop
Turkish 14 / PLS 1
35 7 Missense c.1040A>G (p.Y347C) AHCR** Indian-Pakistani7, Jordanian 10 / PLS, PPP 2
36 7 Deletion c.1047delA 
(p.G349fsX359)
Frameshift & Premature 
stop
Turkish 14 / PLS 1
37 7 Deletion c.1056delT Frameshift & Premature 
stop
French 19 / PLS 1
38 7 Deletion c.1141delC (p.L381fsX393) Frameshift & Premature 
stop
§S Caucasian20, French 19 / PLS 2
39 7 Nonsense c.1286G>A (p.W429X) Premature stop Turkish 14,15 / PLS 4
40 7 Missense c.1287G>C (p. W429C) AHCR** French19 / PLS 1
41 7 Missense c.1360A>G (p.E447G) AHCR** Φ Vietnamese 15 / PLS 1
[A] Novel mutations identified in this study; [20] Zhang et al. 2002; [16] Nakano et al. 2001; [15] Hart et al. 2000c; [17] Zhang et al. 2001; [18] 
Allende et al. 2001; [19] Lefevre et al. 2001; [7]Toomes et al. 1999; [3] Cury et al. 2002; [21] Hart et al. 2002; [10] Hart et al. 2000b; [14] Hart et al. 
1999; [22] Nusier et al. 2002; [9] Hart et al. 2000a. * Proband was a compound heterozygote for the 199–222 del and 458C>T mutations ** Alter-
ation of highly conserved residue. §Probands were compound heterozygote for the 96T>G and 815G>C mutations. §S Proband was a compound 
heterozygote for the 415G>A and 1141delC mutations. φ Proband was a compound heterozygote for the 706G>T and 872G>A mutations. Φ 
Proband was a compound heterozygote for the 898G>A and 1360A>G mutations.BMC Medical Genetics 2003, 4 http://www.biomedcentral.com/1471-2350/4/5
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mutation has also been detected in a homozygous state in
a Spanish PLS patient, suggesting that the HMS and PLS
are clinical variants of the same homozygous cathepsin C
gene mutation [18]. It is possible that a part of the clinical
manifestations in HMS patients (viz., hyperkeratosis and
periodontitis) is caused by a mutation in the CTSC gene
where as other features of HMS (viz., onychogryposis, pes
planus, arachnodactyly, and acroosteolysis) are caused by
mutations in another hitherto undescribed gene. How-
ever, this possibility remains to be proven.
Hart et al. al. [15] have carried out genotype-phenotype
correlation using 22 probands on whom genotype and
phenotype data were available. The categories for geno-
type were mutations in the pro-region and mutations in
the mature enzyme [15]. The categories for phenotypes
were the presence or absence of transgressions of the
hyperkeratosis lesions on the knees and elbows [15]. No
correlation was found as affected subjects with transgres-
sions of dermal lesions onto knees or elbows or both had
mutations in both the pro- and mature regions of the
enzyme [15]. Our analysis on 41 probands suggested a
similar finding. Our analysis also did not find any corre-
lation between the types of mutations (missense, non-
sense, insertion, deletion and splice site) and the presence
or absence of the lesions on the knees or elbows or both
as observed previously by Hart et al. [15].
Conclusions
In this study, we have reported three novel nonsense
mutations responsible for PLS phenotype in three Indian
families. In addition, our review of the literature showed
that the total number of mutations described to date in
the cathepsin C gene, along with the ones reported during
the present study, reaches to 41 including a common
mutation reported in HMS patients.
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